Protembis

Protembis is a medical device company that has developed the ProtEMBisa, an intra-aortic cerebral protection device designed to minimize the risk of stroke and other neurological injuries during transcatheter aortic valve replacement (TAVR) procedures.

The company's core product is a catheter-based system that is inserted through the radial artery in the wrist and positioned in the aorta to deflect embolic debris away from the brain. This addresses a significant unmet need in the rapidly growing TAVR market, where stroke is a major complication.

Protembis' business model is focused on the development and commercialization of this proprietary technology. The company generates revenue through the sale of its cerebral protection device to hospitals and cardiac centers that perform TAVR procedures. Its primary customers are interventional cardiologists and cardiac surgeons.

The company has raised a total of $42.5M in funding over 5 rounds from 13 investors, which has supported the development and clinical testing of its device. Protembis is headquartered in Aachen, Germany, and operates in the medical device sector, specifically within the cardiovascular and neurovascular markets.

Keywords: cerebral protection, TAVR, medical device, stroke prevention, cardiovascular, neurovascular, embolic protection, interventional cardiology, structural heart, aortic stenosis